心肌肌球蛋白结合蛋白C对急性心肌梗死早期诊断的增量价值
本研究为国际前瞻性研究的二次分析,纳入4735例急诊疑似NSTEMI患者,比较新型自动化免疫检测cMyC与hs-cTnT/I的早期诊断性能。cMyC对NSTEMI的判别能力高于hs-cTnT,尤其胸痛发作≤3小时者;hs-cTn联合cMyC的单次采血双标志物策略将分诊效率从26.8%提高至60.0%且不损害安全性。
要点
- cMyC对NSTEMI的AUC为0.943,高于hs-cTnT的0.936(P=0.008)。
- 胸痛≤3小时者cMyC优势更明显(AUC 0.939 vs 0.921,P<0.001)。
- hs-cTnT联合cMyC策略分诊效率由26.8%升至60.0%,安全性未受损。
核心结论
- cMyC在NSTEMI早期诊断中较hs-cTn提供显著增量价值,提高判别能力并使更多患者安全快速排除NSTEMI。
- 单次采血双标志物策略因简便和快速决策在繁忙急诊环境中尤其有吸引力。
研究设计与样本
- 国际前瞻性研究的二次分析,纳入急诊疑似NSTEMI成人患者4735例,其中854例(18%)诊断为NSTEMI。
- 就诊时检测cMyC、hs-cTnT和hs-cTnI,最终诊断由两名独立心内科医生中心化裁定且对cMyC值设盲。
- 结果在独立国际队列中进行外部验证。
主要发现
- cMyC对NSTEMI的AUC为0.943(95%CI 0.936-0.95),高于hs-cTnT的0.936(95%CI 0.929-0.944),P=0.008。
- 胸痛发作≤3小时患者中,cMyC的AUC为0.939(95%CI 0.928-0.951),hs-cTnT为0.921(95%CI 0.907-0.936),P<0.001。
- 双标志物策略将总体分诊效率从26.8%(仅hs-cTnT)提高至60.0%(hs-cTnT联合cMyC),且不损害 index visit 期间的安全性。
- 双标志物策略排除的患者多达3倍,但30天、1年和5年心血管死亡或MI的累积发生率相当。
- hs-cTnI及外部验证队列中观察到相似结果。
关键数值与推荐
- 安全性定义为排除index NSTEMI的敏感度和阴性预测值;分诊效率定义为分诊至排除或纳入的患者比例。
- 诊断终点为index NSTEMI;预后终点为30天、1年和5年心血管死亡或MI。
临床怎么用
- 在急诊疑似NSTEMI患者中,可考虑单次采血同时检测hs-cTn和cMyC以快速分诊。
- 双标志物策略有助于安全排除更多NSTEMI患者,尤其适用于胸痛发作早期(≤3小时)者。
局限性
- 本研究为二次分析,原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiac myosin-binding protein C (cMyC) is a cardiac-specific sarcomeric protein with faster release kinetics compared with those of high-sensitivity cardiac troponin (hs-cTn). OBJECTIVES: The aim of this study was to compare the diagnostic performance of cMyC, measured with a novel prototype automated immunoassay, with high-sensitivity cardiac troponin T (hs-cTnT) and high-sensitivity cardiac troponin I (hs-cTnI) for the early diagnosis of non-ST-segment elevation myocardial infarction (NSTEMI). Furthermore, we derived a single blood draw dual-biomarker strategy combining hs-cTn and cMyC and compared it with the hs-cTnT/I-only strategy endorsed by the European Society of Cardiology. METHODS: This was a secondary analysis from an international prospective study recruiting adult patients presenting to the emergency department (ED) with suspected NSTEMI. cMyC, hs-cTnT, and hs-cTnI concentrations were measured upon ED presentation. Final diagnoses were centrally adjudicated by 2 independent cardiologists blinded to cMyC values. To compare the single- and dual-biomarker strategy, safety (defined as the sensitivity and negative predictive value for ruling out index NSTEMI) and triage efficacy (defined as the proportion of patients triaged to either rule-out or rule-in) were assessed. The diagnostic endpoint was index NSTEMI. The prognostic endpoint was 30-day, 1-year, and 5-year cardiovascular death or MI. Findings were externally validated in an independent international cohort. RESULTS: Among 4,735 eligible patients, 854 (18%) were diagnosed with NSTEMI. The discrimination for NSTEMI at presentation was higher for cMyC (area under the curve [AUC]: 0.943; 95% CI: 0.936-0.95) than for hs-cTnT (AUC: 0.936; 95% CI: 0.929-0.944; P = 0.008). Differences were mainly driven by patients with chest pain onset ≤3 hours (AUC of 0.939 [95% CI: 0.928-0.951] vs 0.921 [95% CI: 0.907-0.936], respectively; P < 0.001). The dual-biomarker strategy increased overall triage efficacy from 26.8% (hs-cTnT only) to 60.0% (hs-cTnT and cMyC), without compromising safety during the index visit. Despite identifying up to 3 times more patients for rule-out, the dual-biomarker strategy showed comparable cumulative incidences of cardiovascular death or myocardial infarction at 30 days, 1 year, and 5 years. Similar results were observed with hs-cTnI and in the external validation cohort. CONCLUSIONS: CMyC adds significant incremental value to hs-cTn values in the early diagnosis of NSTEMI, improving diagnostic discrimination and enabling more patients to be safely and immediately ruled out for NSTEMI. The single blood draw dual-biomarker strategy is particularly attractive in busy ED settings due to its simplicity and quick time-to-decision. (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE]; NCT00470587).
引用
- Lopez-Ayala, Boeddinghaus, Koechlin, et al. Incremental Value of Cardiac Myosin-Binding Protein C for the Early Diagnosis of Acute Myocardial Infarction. J Am Coll Cardiol. 2025. PMID: 41222525. doi:10.1016/j.jacc.2025.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。